Income Statement (TTM)
XTL Biopharmaceuticals Ltd. - Depositary Receipt (Common Stock) Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2024 09-30 |
2024 12-31 |
|
|---|---|---|
| Revenue | 0 | 0 |
| Change (%) | 880.43 | |
| % of Revenue | 100.00 | 100.00 |
| Cost Of Sales | 0 | |
| Change (%) | ||
| % of Revenue | 99.33 | |
| Gross Operating Profit | 0 | 0 |
| Change (%) | -93.48 | |
| % of Revenue | 100.00 | 0.67 |
| SG&A | 2 | 2 |
| Change (%) | 35.40 | |
| % of Revenue | 3,334.78 | 460.53 |
| R&D | 0 | 0 |
| Change (%) | 36.11 | |
| % of Revenue | 156.52 | 21.73 |
| OpEx | 2 | 3 |
| Change (%) | 63.33 | |
| % of Revenue | 3,491.30 | 581.60 |
| Operating Income | -2 | -2 |
| Change (%) | 39.23 | |
| % of Revenue | -3,391.30 | -481.60 |
| Interest Expense | -0 | -0 |
| Change (%) | -24.32 | |
| % of Revenue | -80.43 | -6.21 |
| Net Income | -1 | -1 |
| Change (%) | -2.75 | |
| % of Revenue | -2,295.65 | -227.72 |
Source: Capital IQ
